BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35155685)

  • 1. A Novel
    Zhang L; Du J; Song Q; Zhang C; Wu X
    J Immunol Res; 2022; 2022():1178874. PubMed ID: 35155685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
    Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
    Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
    Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
    Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
    Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
    Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors.
    Bulgarelli J; Tazzari M; Granato AM; Ridolfi L; Maiocchi S; de Rosa F; Petrini M; Pancisi E; Gentili G; Vergani B; Piccinini F; Carbonaro A; Leone BE; Foschi G; Ancarani V; Framarini M; Guidoboni M
    Front Immunol; 2019; 10():2353. PubMed ID: 31649669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model.
    Yazdani M; Nikpoor AR; Gholizadeh Z; Mohamadian Roshan N; Seifalian A; Jaafari MR; Badiee A
    Int Immunopharmacol; 2021 Sep; 98():107833. PubMed ID: 34352472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.
    Liu H; Innamarato PP; Kodumudi K; Weber A; Nemoto S; Robinson JL; Crago G; McCardle T; Royster E; Sarnaik AA; Pilon-Thomas S
    Oncotarget; 2016 Jun; 7(25):37893-37905. PubMed ID: 27177220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.
    Hong S; Li H; Qian J; Yang J; Lu Y; Yi Q
    Clin Exp Immunol; 2012 Nov; 170(2):167-77. PubMed ID: 23039887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.
    Thurner B; Haendle I; Röder C; Dieckmann D; Keikavoussi P; Jonuleit H; Bender A; Maczek C; Schreiner D; von den Driesch P; Bröcker EB; Steinman RM; Enk A; Kämpgen E; Schuler G
    J Exp Med; 1999 Dec; 190(11):1669-78. PubMed ID: 10587357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8(+) T cell/regulatory T cells in tumour.
    Song S; Zhang K; You H; Wang J; Wang Z; Yan C; Liu F
    Clin Exp Immunol; 2010 Oct; 162(1):75-83. PubMed ID: 20735440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity.
    Takeda A; Homma S; Okamoto T; Kufe D; Ohno T
    Eur J Clin Invest; 2003 Oct; 33(10):897-904. PubMed ID: 14511362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan gel vaccine protects against tumour growth in an intracaecal mouse model of cancer by modulating systemic immune responses.
    Highton AJ; Girardin A; Bell GM; Hook SM; Kemp RA
    BMC Immunol; 2016 Oct; 17(1):39. PubMed ID: 27756214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic immune response induced by electrofusion of dendritic and tumor cells.
    Tanaka H; Shimizu K; Hayashi T; Shu S
    Cell Immunol; 2002 Nov; 220(1):1-12. PubMed ID: 12718934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
    Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
    Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.